ChemicalBook >> CAS DataBase List >>Parecoxib

Parecoxib

CAS No.
1709956-95-5
Chemical Name:
Parecoxib
Synonyms
Parecoxib;ValdecoxibImpurity39;Parecoxib Impurity 33;Valdecoxib Impurity N;3-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonyl Chloride;Benzenesulfonyl chloride, 3-(5-methyl-3-phenyl-4-isoxazolyl)-
CBNumber:
CB6951641
Molecular Formula:
C16H12ClNO3S
Molecular Weight:
333.79
MDL Number:
MOL File:
1709956-95-5.mol
Last updated:2024-03-19 15:37:50

Parecoxib Properties

Melting point 165-167°C
Boiling point 459.4±45.0 °C(Predicted)
Density 1.340±0.06 g/cm3(Predicted)
storage temp. Refrigerator
solubility DMSO (Slightly), Methanol (Slightly)
pka -3.44±0.50(Predicted)
form Solid
color White to Off-White
FDA UNII 9TUW81Y3CE
ATC code M01AH04

Pharmacokinetic data

Protein binding 98%
Excreted unchanged in urine <5 (as valdecoxib)
Volume of distribution 55 Litres
Biological half-life 8 (as valdecoxib) / Unchanged

Parecoxib price

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
TRC M305725 3-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonylChloride 1709956-95-5 1mg $165 2021-12-16 Buy
Usbiological 462055 Parecoxib 1709956-95-5 10mg $305 2021-12-16 Buy
Product number Packaging Price Buy
M305725 1mg $165 Buy
462055 10mg $305 Buy

Parecoxib Chemical Properties,Uses,Production

Uses

Anti-inflammatory; analgesic (cyclooxygenase COX-2 inhibitor).

Uses

3-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonyl Chloride is an Impurity of Parecoxib Sodium (P193275), an anti-inflammatory, analgesic.

Clinical Use

Parecoxib is a pro-drug of valdecoxib administered IM or IV for perioperative analgesic and anti-inflammatory use. As a pro-drug, it undergoes rapid in vivo hydrolysis to valdecoxib.Parecoxib at greater than 20 mg has analgesic activity superior to that of placebo and similar to that of parenteral 30 or 60 mg of ketorolac in patients with postoperative dental pain. A significant adverse effect is drug hypersensitivity. Parecoxib is currently marketed worldwide but has not been approved for use in the United States.

Synthesis

The acylation of 4-(5-methyl- 3-phenylisoxazol-4-yl)benzenesulfonamide (valdecoxib), with propionic anhydride in a solution of triethanolamine (TEA) and 4-dimethylaminophenol (DMAP) in tetrahydrofuran gives N-propionamide, which is treated with NaOH in ethanol to give the sodium salt of parecoxib .

Drug interactions

Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia.
Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage).
Antibacterials: possible increased risk of convulsions with quinolones.
Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparin, dabigatran and edoxaban.
Antidepressants: increased risk of bleeding with SSRIs and venlafaxine.
Antidiabetics: possibly enhanced effect of sulphonylureas.
Antiepileptics: possibly enhanced effect of phenytoin.
Antifungals: if used with fluconazole reduce the dose of parecoxib.
Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir.
Ciclosporin: potential for increased risk of nephrotoxicity.
Cytotoxics: reduced excretion of methotrexate, (possible increased risk of toxicity); increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity; possible antagonism of diuretic effect; increased risk of hyperkalaemia with potassium-sparing diuretics.
Lithium: reduced excretion of lithium (risk of toxicity).
Pentoxifylline: possibly increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity.

Metabolism

Parecoxib is rapidly and almost completely converted to valdecoxib and propionic acid.
Elimination of valdecoxib is by extensive hepatic metabolism involving multiple pathways, including cytochrome P 450 (CYP) 3A4 and CYP2C9 isoenzymes and glucuronidation (about 20%) of the sulphonamide moiety. Excretion is mainly via the urine with about 70% of a dose appearing as inactive metabolites. No unchanged parecoxib is found in the urine with only trace amounts in the faeces.

Parecoxib Preparation Products And Raw materials

Raw materials

Preparation Products

Parecoxib Suppliers

Global( 46)Suppliers
Supplier Tel Email Country ProdList Advantage
Standardpharm Co. Ltd.
86-714-3992388 overseasales1@yongstandards.com United States 14336 58
China National Standard Pharmaceutical Corporation Limited
+8615391658522 overseasales@yongstandards.com China 11927 58
BOC Sciences 1-631-485-4226; 16314854226 info@bocsci.com United States 14059 65
S.Z. PhyStandard Bio-Tech. Co., Ltd. 4000505016; 13380397412 3001272453@qq.com China 5000 50
Shanghai Kewel Chemical Co., Ltd. 021-64609169 18901607656 greensnown@163.com China 9912 50
Hubei Yangxin Medical Technology Co., Ltd. 15374522761 3003392093@qq.com China 7811 55
Shenzhen Polymeri Biochemical Technology Co., Ltd. +86-400-002-6226 13028896684 sales@rrkchem.com China 55477 58
Guangzhou Dreampharm Biotechnology Co., Ltd. 17825480238 3008233717@qq.com China 9844 12
Jinan blalong chemical co. LTD 2710913286@.com 1513643261@qq.com China 14253 58
Meng Cheng Technology (Shanghai) Co., LTD 400-820-6829 sales@mitachieve.com China 8864 58
Parecoxib Valdecoxib Impurity N Parecoxib Impurity 33 3-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonyl Chloride Benzenesulfonyl chloride, 3-(5-methyl-3-phenyl-4-isoxazolyl)- ValdecoxibImpurity39 1709956-95-5